UBS AM’s Jazz Pharmaceuticals JAZZ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $136K | Sell |
563
-147,201
| -100% | -$32.2M | ﹤0.01% | 2784 |
|
|
2026
Q1 | $27.9M | Sell |
147,764
-559
| -0.4% | -$97.7K | 0.01% | 772 |
|
|
2025
Q4 | $25.2M | Sell |
148,323
-21,364
| -13% | -$3.28M | 0.01% | 775 |
|
|
2025
Q3 | $22.4M | Sell |
169,687
-104,364
| -38% | -$12.5M | ﹤0.01% | 787 |
|
|
2025
Q2 | $29.1M | Buy |
274,051
+76,877
| +39% | +$8.35M | 0.01% | 897 |
|
|
2025
Q1 | $24.5M | Buy |
197,174
+7,954
| +4% | +$1.04M | 0.01% | 881 |
|
|
2024
Q4 | $23.3M | Buy |
189,220
+15,142
| +9% | +$1.78M | 0.01% | 894 |
|
|
2024
Q3 | $19.4M | Buy |
174,078
+100,112
| +135% | +$11M | 0.01% | 961 |
|
|
2024
Q2 | $7.89M | Sell |
73,966
-167,719
| -69% | -$18.4M | ﹤0.01% | 1243 |
|
|
2024
Q1 | $29.1M | Buy |
241,685
+8,805
| +4% | +$1.08M | 0.01% | 701 |
|
|
2023
Q4 | $28.6M | Sell |
232,880
-4,192
| -2% | -$523K | 0.01% | 707 |
|
|
2023
Q3 | $30.7M | Sell |
237,072
-59,825
| -20% | -$7.97M | 0.01% | 673 |
|
|
2023
Q2 | $43.4M | Hold |
296,897
| – | – | 0.02% | 589 |
|
|
2023
Q1 | $43.4M | Sell |
296,897
-5,324
| -2% | -$788K | 0.02% | 589 |
|
|
2022
Q4 | $48.1M | Buy |
302,221
+13,204
| +5% | +$1.94M | 0.03% | 555 |
|
|
2022
Q3 | $38.5M | Sell |
289,017
-113
| -0% | -$17.2K | 0.02% | 615 |
|
|
2022
Q2 | $45.1M | Sell |
289,130
-38,876
| -12% | -$5.98M | 0.02% | 570 |
|
|
2022
Q1 | $51.1M | Sell |
328,006
-232,935
| -42% | -$33.8M | 0.02% | 603 |
|
|
2021
Q4 | $71.5M | Buy |
560,941
+224,125
| +67% | +$29.5M | 0.03% | 572 |
|
|
2021
Q3 | $43.9M | Sell |
336,816
-25,703
| -7% | -$3.88M | 0.02% | 661 |
|
|
2021
Q2 | $64.4M | Buy |
362,519
+9,306
| +3% | +$1.61M | 0.03% | 576 |
|
|
2021
Q1 | $58.1M | Sell |
353,213
-39,435
| -10% | -$6.49M | 0.03% | 585 |
|
|
2020
Q4 | $64.8M | Buy |
392,648
+11,449
| +3% | +$1.71M | 0.03% | 519 |
|
|
2020
Q3 | $54.4M | Sell |
381,199
-29
| -0% | -$3.6K | 0.03% | 497 |
|
|
2020
Q2 | $42.1M | Sell |
381,228
-24,175
| -6% | -$2.67M | 0.03% | 545 |
|
|
2020
Q1 | $40.4M | Sell |
405,403
-7,430
| -2% | -$961K | 0.03% | 515 |
|
|
2019
Q4 | $61.6M | Buy |
412,833
+71,942
| +21% | +$9.79M | 0.04% | 475 |
|
|
2019
Q3 | $43.7M | Sell |
340,891
-18,271
| -5% | -$2.45M | 0.03% | 553 |
|
|
2019
Q2 | $51.2M | Buy |
359,162
+2,483
| +0.7% | +$334K | 0.04% | 511 |
|
|
2019
Q1 | $51M | Buy |
356,679
+82,657
| +30% | +$10.8M | 0.04% | 477 |
|
|
2018
Q4 | $34M | Sell |
274,022
-5,904
| -2% | -$876K | 0.03% | 573 |
|
|
2018
Q3 | $47.1M | Buy |
279,926
+13,061
| +5% | +$2.25M | 0.04% | 514 |
|
|
2018
Q2 | $46M | Buy |
266,865
+39,581
| +17% | +$6.47M | 0.04% | 530 |
|
|
2018
Q1 | $34.3M | Buy |
227,284
+35,511
| +19% | +$5.21M | 0.03% | 620 |
|
|
2017
Q4 | $25.8M | Buy |
191,773
+15,739
| +9% | +$2.18M | 0.02% | 682 |
|
|
2017
Q3 | $25.7M | Buy |
176,034
+30,263
| +21% | +$4.58M | 0.02% | 675 |
|
|
2017
Q2 | $22.7M | Buy |
145,771
+6,805
| +5% | +$1.04M | 0.02% | 697 |
|
|
2017
Q1 | $20.2M | Sell |
138,966
-583
| -0.4% | -$75.9K | 0.02% | 716 |
|
|
2016
Q4 | $15M | Sell |
139,549
-15,163
| -10% | -$1.69M | 0.02% | 770 |
|
|
2016
Q3 | $18.8M | Buy |
154,712
+11,112
| +8% | +$1.5M | 0.02% | 703 |
|
|
2016
Q2 | $20.3M | Sell |
143,600
-1,659
| -1% | -$245K | 0.02% | 675 |
|
|
2016
Q1 | $19M | Buy |
145,259
+12,328
| +9% | +$1.53M | 0.02% | 684 |
|
|
2015
Q4 | $18.7M | Sell |
132,931
-2,878
| -2% | -$399K | 0.02% | 690 |
|
|
2015
Q3 | $18M | Buy |
135,809
+8,988
| +7% | +$1.55M | 0.02% | 709 |
|
|
2015
Q2 | $22.3M | Buy |
126,821
+957
| +0.8% | +$172K | 0.02% | 687 |
|
|
2015
Q1 | $21.7M | Buy |
125,864
+10,802
| +9% | +$1.85M | 0.02% | 683 |
|
|
2014
Q4 | $18.8M | Buy |
115,062
+20,957
| +22% | +$3.48M | 0.02% | 717 |
|
|
2014
Q3 | $15.1M | Buy |
94,105
+43,907
| +87% | +$6.75M | 0.02% | 746 |
|
|
2014
Q2 | $7.38M | Buy |
50,198
+2,800
| +6% | +$388K | 0.01% | 939 |
|
|
2014
Q1 | $6.57M | Sell |
47,398
-49,500
| -51% | -$7.45M | 0.01% | 970 |
|
|
2013
Q4 | $12.3M | Buy |
96,898
+15,400
| +19% | +$1.59M | 0.01% | 772 |
|
|
2013
Q3 | $7.5M | Sell |
81,498
-7,600
| -9% | -$613K | 0.01% | 882 |
|
|
2013
Q2 | $6.12M | Buy |
+89,098
| New | +$5.45M | 0.01% | 907 |
|
Other funds holding JAZZ
UBS AM's JAZZ Position: Q2 2026 in Review
UBS AM reduced its Jazz Pharmaceuticals (JAZZ) stake by 100% in Q2 2026, selling an estimated $32.2M and leaving 563 shares worth $136K. The position accounts for ﹤0.01% of the portfolio, ranked #2784.
UBS AM first reported a position in JAZZ in Q2 2013 and has held it in 53 quarters since. The position peaked at $71.5M in Q4 2021. 642 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.
- UBS AM held 563 shares of Jazz Pharmaceuticals worth $136K as of Q2 2026.
- UBS AM sold 147,201 Jazz Pharmaceuticals shares in Q2 2026, an estimated $32.2M.
- Jazz Pharmaceuticals made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #2784 holding.
- UBS AM first reported a position in Jazz Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
- UBS AM's Jazz Pharmaceuticals position peaked at $71.5M in Q4 2021.
- 642 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.
Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.